Month: September 2026

OÜ Krulli Kodud, a joint venture between OÜ Merko Kodud, part of the AS Merko Ehitus group, and AS Krulli Kvartal, has decided to launch a new residential development at 1b Volta street in the Krulli Quarter. The project comprises three apartment buildings with a total of 23 apartments, scheduled for completion in early 2028.

Apartments in the Krulli homes (krullikodud.ee) range in size from 44 to 121 square metres, with prices starting from 6,600 euros per square metre. Each apartment has a balcony or terrace. Storage units and parking spaces are located on the underground parking level. The development will also include bicycle and pram storage facilities, as well as a shared hobby and leisure space for residents of the three buildings.

The Krulli development area covers 10 hectares, with more than 100,000 square metres of above-ground gross floor area planned. Over the next ten years, nearly 20 buildings are planned for the Krulli Quarter, comprising more than 600 homes and commercial premises providing workplaces for approximately 3,000 people. The buildings will be surrounded by a modern living environment.

The Volta 1b apartment buildings form part of the first development phase of the Krulli Quarter, which will also include an event centre, scheduled for completion in 2027, and the Kasvuhoone business and innovation centre, scheduled for completion in 2028. The first phase also includes the construction of the Bob W aparthotel and a mixed-use residential and commercial building, as well as the reconstruction of an existing commercial building.

Residential development projects in the Krulli Quarter are being developed by OÜ Krulli Kodud, a joint venture established in 2025 and owned equally by OÜ Merko Kodud and AS Krulli Kvartal. AS Merko Ehitus Eesti is the main contractor for the construction of the buildings in the quarter’s first development phase.

OÜ Merko Kodud (merko.ee/kodud) is Estonia’s best-known and most trusted residential real estate developer. To ensure the best quality, convenience and assurance for home buyers, Merko manages all phases of the development: planning, design, construction, sales and warranty service.

Additional information: CEO of OÜ Merko Kodud, Mr. Indrek Tarto, phone: +372 680 5105.

Urmas Somelar
Head of Finance
AS Merko Ehitus
+372 650 1250
urmas.somelar@merko.ee

AS Merko Ehitus (group.merko.ee) group companies construct buildings and infrastructure and develop real estate. We create a better living environment and build the future. We operate in Estonia, Latvia, and Lithuania. As at the end of 2025, the group employed 613 people, and the group’s revenue for 2025 was EUR 311 million.

Attachments

• Krulli kodud visualiseering-2
• Krulli kodud visualiseering-1

Amsterdam, 24 September 2026 (Regulated Information) — AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) has applied to list its shares on the Frankfurt Stock Exchange, with the first day of trading expected to be September 30, 2026.

As previously announced, AMG does not plan to issue or offer any new shares in connection with the secondary listing in Frankfurt. Euronext Amsterdam will continue to be AMG’s primary listing.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

This press release contains regulated information as defined in the Dutch Financial Markets Supervision Act (Wet op het financieel toezicht).

About AMG

AMG’s mission is to provide critical materials and related process technologies to advance a less carbon-intensive world. To this end, AMG is focused on the production and development of energy storage materials such as lithium, vanadium, and tantalum. In addition, AMG’s products include highly engineered systems to reduce CO₂ in aerospace engines, as well as critical materials addressing CO₂ reduction in a variety of other end use markets.

AMG’s Lithium segment spans the lithium value chain, reducing the CO₂ footprint of both suppliers and customers. AMG’s Vanadium segment is the world’s market leader in recycling vanadium from oil refining residues, spanning the Company’s vanadium, molybdenum, titanium, and chrome businesses. AMG’s Technologies segment is the established world market leader in advanced metallurgy and provides equipment engineering to the aerospace engine sector globally. It serves as the engineering home for the Company’s fast-growing LIVA batteries, NewMOX SAS formed to span the nuclear fuel market, and AMG’s mineral processing operations in antimony.

With approximately 3,500 employees, AMG operates globally with production facilities in Germany, the United Kingdom, France, the United States, China, Mexico, Brazil, and India, and has sales and customer service offices in Japan (www.amg-nv.com).

For further information, please contact:
AMG Critical Materials N.V.        +49 176 1000 73 14
Thomas Swoboda
tswoboda@amg-nv.com

Disclaimer

Certain statements in this press release are not historical facts and are “forward looking.” Forward looking statements include statements concerning AMG’s plans, expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans and intentions relating to acquisitions, AMG’s competitive strengths and weaknesses, plans or goals relating to forecasted production, reserves, financial position and future operations and development, AMG’s business strategy and the trends AMG anticipates in the industries and the political and legal environment in which it operates and other information that is not historical information. When used in this press release, the words “expects,” “believes,” “anticipates,” “plans,” “may,” “will,” “should,” and similar expressions, and the negatives thereof, are intended to identify forward looking statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that the predictions, forecasts, projections and other forward-looking statements will not be achieved. These forward-looking statements speak only as of the date of this press release. AMG expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained herein to reflect any change in AMG’s expectations with regard thereto or any change in events, conditions, or circumstances on which any forward-looking statement is based.

Attachment

• Dual Listing Filing Press Release

Geneva, Switzerland, September 24, 2026 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on September 28, 2026.

Title:  Addex Therapeutics Reports 2026 Half-Year and Second Quarter Financial Results and Provides Corporate Update
Date: September 28, 2026
Time: 16:00 CET (15:00 BST / 10:00 EDT / 07:00 PDT)

Joining the Conference Call:

1. Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
2. In the 10 minutes prior to the call start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.

Webcast registration link: Registration webcast

Conference call registration link: Registration conference media

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com
  
Contacts: 

Tim Dyer  Chief Executive Officer  Telephone: +41 22 884 15 55  PR@addextherapeutics.com

Mike Sinclair  Partner, Halsin Partners  +44 (0)7968 022075  msinclair@halsin.com

Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

RIBER REPORTS IMPROVED RESULTS FOR THE FIRST HALF OF 2026

• Revenues of €12.7m (+19%) and gross margin of €5.1m (+31%), representing 39.8% of revenues
• Positive net income of €0.2m, compared with -€0.8m in the first half of 2025
• €6m in financing secured for the industrialization of ROSIE II
• 2026 outlook: revenues expected to be in line with 2025, subject to obtaining an export license for Asia

Bezons, September 24, 2026 – 7:00 a.m. – RIBER, a global market leader for semiconductor industry equipment, announces its results for the first half of 2026. In a complex international environment, RIBER recorded revenue growth and improved earnings. The Company is also continuing to implement its strategic roadmap, having secured €6 million in financing to accelerate the industrialization of ROSIE II.

(€ millions)	H1 2026 (6 months)	H1 2025 (6 months)	Change		2025 (12 months)
Revenues Systems revenues	12.7 7.7	10.7 7.8	+19%		40.3
			-1%		30.9
Services and accessories revenues	5.1	3.0	+71%		9.4
Gross margin as % of revenues	5.1 39.8%	3.9 36.2%	+31%		15.6 38.6%
Operating income as % of revenues	0.1 0.8%	(0.7) (6.1%)	+€0.8m		5.1 12.7%
Net income as % of revenues	0.2 1.6%	(0.8) (7.6%)	+€1.0m		5.2 13.0%

First-half highlights

In a complex international environment, RIBER recorded a 19% increase in revenues and positive net income for the first half of 2026. This performance was driven by strong momentum in Services and Accessories and resilient Systems sales.

At the same time, RIBER is continuing to roll out ROSIE (RIBER Oxide Silicon Epitaxy), its platform dedicated to the growth of functional oxides on 300 mm silicon wafers, designed in accordance with SEMI industry standards. The technology targets integrated silicon photonics, with potential applications in electro-optical components for telecommunications and data centers, as well as in certain quantum architectures. The second ROSIE system was shipped in July 2026 to a major quantum computing player in the United States.

To support the next stage of ROSIE’s development, RIBER has secured €6 million in bank financing for the industrialization of ROSIE II, a dual-chamber cluster production platform.

Revenues

Revenues for the first half of 2026 amounted to €12.7 million, up 19% compared with the first half of 2025.

Systems revenues amounted to €7.7 million, down 1% from the first half of 2025. Services and Accessories revenues rose 71% to €5.1 million, against a favorable comparison base.

Results

Given the traditional seasonality of RIBER’s sales, first-half results cannot be extrapolated to the full year.

Gross margin came to €5.1 million, up 31% compared with the first half of 2025. The gross margin rate therefore reached 39.8% of revenue, compared with 36.2% one year earlier.

Operating income was positive at €0.1 million, compared with a loss of €0.7 million in the first half of 2025. This €0.8 million improvement reflects revenue growth, the higher gross margin rate and disciplined operating expense management.

Net income amounted to €0.2 million, compared with a loss of €0.8 million in the first half of 2025. It includes net financial income of €0.1 million.

Cash position and balance sheet

Shareholders’ equity at end-June 2026 stood at €25.7 million, compared with €27.3 million at year-end 2025. The decrease mainly reflects the result for the period and the €2.1 million distribution to shareholders from the issue premium account in June 2026.

At June 30, 2026, the cash position amounted to €5.2 million, compared with €7.5 million at December 31, 2025 and €2.5 million at June 30, 2025.

Financial debt (excluding IFRS 16) amounted to €6.4 million, compared with €1.4 million at December 31, 2025 and €2.3 million at June 30, 2025. It includes €6.0 million in bank borrowings arranged during the first half with Bpifrance and leading French banks.

Net cash/(debt)¹ therefore amounted to (€1.2) million at June 30, 2026, compared with €0.2 million one year earlier.

Order book at June 30, 2026

Commercial activity remains strong, particularly in applications related to datacom and quantum technologies.

At June 30, 2026, the order book stood at €26.8 million, down by 3% year on year. It was affected by export restrictions to Asia, which prevented more than €8 million in orders from being secured, and by longer decision-making cycles at certain customers.

Systems orders amounted to €16.5 million (-27%) and comprised orders for 4 systems, including 3 production systems and 1 ROSIE platform. This order book does not include the order announced in July 2026 for a production system in Europe, scheduled for delivery in 2027.

Services and Accessories orders rose sharply to €10.3 million (+98%), supported in particular by sales of spare parts for recently ordered equipment and several upgrade projects for long-standing customers in North America.

Outlook

Continued industrialization of ROSIE

RIBER is continuing to execute its roadmap with its first ROSIE II production system now under construction. The system will support further technological maturation of the platform, accelerate the qualification of BTO/STO² processes under industrial operating conditions and prepare the technology for commercial rollout.

RIBER may use this first ROSIE II system to produce technology wafers or allocate it to an industrial customer. The first BTO/STO samples developed through the partnership with the Novo Nordisk Foundation Quantum Computing Programme (NQCP) will be available in the fourth quarter of 2026. Several laboratories and industrial companies have confirmed their interest in technology through wafer pre-orders.

In addition, RIBER has been invited to participate in the establishment of major industrial and technological partnerships, helping to support the development of new applications.

2026 outlook

RIBER’s addressable markets continue to benefit from favorable structural trends, particularly in photonics, artificial intelligence and quantum technologies. The Company also continues to see sustained demand for its Services and Accessories.

Subject to obtaining an export license, RIBER expects revenues to be broadly in line with 2025.

Governance

At its meeting on September 22, 2026, RIBER’s Board of Directors acknowledged the resignation of Mr. Nicolas Grandjean as an independent director for professional reasons. The Board warmly thanks Mr. Grandjean for his contribution to its work and for his commitment throughout his term of office.

Annie Geoffroy, Chair and Chief Executive Officer of RIBER, concluded:
“The first half of 2026 confirms the strength of our core business in an international environment that remains complex. Strong momentum in Services and Accessories, together with sustained interest in our technologies, are encouraging signs.

We are also reaching an important milestone, with the support of our financial partners, as we move forward with the construction of ROSIE II. This new platform will enable us to accelerate process qualification and prepare for technology’s commercial deployment. At the same time, we are continuing to strengthen our product offering by combining epitaxy and deposition technologies and developing process automation solutions.

We are therefore continuing to execute our roadmap, with the ambition of strengthening our offering around our established technologies and developing new opportunities in photonics, quantum technologies and advanced deposition technologies.”

Agenda: 2026 full-year revenues on February 3, 2027, before the start of trading.

The condensed consolidated half-year accounts have not been subject to an audit or a limited review by the statutory auditors. They were approved by the Board of Directors on September 22, 2026. The half-year financial report is available in French on the company website (www.riber.com).

About RIBER

Founded in 1964, RIBER is the global leader for molecular beam epitaxy (MBE) equipment. The Company designs and manufactures solutions for the semiconductor industry and supports its customers – industrial players and research laboratories – with a comprehensive range of services and scientific and technical support (hardware and software), aimed at optimizing equipment performance and yield.

RIBER’s technologies are at the core of the development of advanced semiconductor devices, particularly for applications related to artificial intelligence, data infrastructure, telecommunications and photonics. With the launch of ROSIE (RIBER Oxide on Silicon Epitaxy), a platform dedicated to silicon-based integrated photonics compatible with 300 mm production lines, RIBER is opening up new opportunities in high-growth markets.

Positioned in strategic technology segments, RIBER also contributes to advances in research and quantum technologies.

RIBER is recognized as an ‘Innovative Company’ by Bpifrance” and is listed on the Euronext Growth Paris market (ISIN: FR0000075954).

www.riber.com  

Contacts

RIBER
Annie Geoffroy | tel : +33 (0)1 39 96 65 00 | invest@riber.com

ACTUS FINANCE & COMMUNICATION
Cyril Combe – Investors relations | tel : +33 (0)1 53 65 37 94 | ccombe@actus.fr
Serena Boni – Press relations | tel : +33 (0)4 72 18 04 92 | sboni@actus.fr

---

1 Balance-sheet cash position net of all financial debt (excluding IFRS 16).
2 Barium Titanate Oxide (BTO) et Strontium Titanate Oxide (STO)

Attachment

• CP_Riber-résultats_S1_2026_E

OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — Scancell Holdings plc (AIM: SCLP) (“Scancell”, or the “Company”), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that, further to its announcement on 23 July 2026 regarding the planned merger with Neuphoria Therapeutics Inc. (“Neuphoria”) and financing to conduct the registrational Phase 3 study for iSCIB1+ and a proposed listing on Nasdaq (the “Merger and Financing Announcement”), it has entered into a loan agreement (the “Loan Agreement”) with certain funds and accounts managed by BlackRock (the “Lender”), for a loan facility of up to US$25,000,000 (the “Loan Facility”).

The Loan Facility is available in four tranches. For the first three tranches, a portion of each is convertible into Ordinary Shares at the Lender’s option, totalling up to US $5,000,000.

The Company intends to draw down US$7,000,000 under the Loan Facility following, and conditional upon, shareholder approval of the Loan Facility at the EGM. Further tranches totalling US$8,000,000 are expected to be available following, and conditional upon, completion of the US Listing Transactions and the expected upcoming opening of the first clinical site for the Phase 3 study for iSCIB1+. These tranches are expected to be drawn following completion of the US Listing Transactions.

The remaining tranche may be drawn until 31 December 2027 subject to a minimum equity fundraising threshold.

Dr Phil L’Huillier, CEO of Scancell, said: “The debt facility is an important part of an equity and debt package in conjunction with the planned merger that allows Scancell to proceed at pace to initiate and execute the global registrational Phase 3 trial for its lead programme, iSCIB1+.”

The Phase 3 trial received IND clearance from the FDA in January 2026. Following Scancell’s recent UK Financing, Phase 3 initiation activities are underway and the Company is on track to commence the trial by the end of 2026. Initial progression free survival (“PFS”) data, which could support accelerated approval under our trial design, is targeted for the second half of 2028.

Further terms of the Loan Facility

Amounts advanced under the Loan Facility are repayable, following an 18 month interest only period, in 24 equal monthly instalments of principal and interest, or in 18 equal monthly instalments of principal and interest commencing after 24 months if the Company has raised cumulative equity funding of at least US$100,000,000 (inclusive of the proceeds of the UK Placing and the Retail Offer). The Loan Facility must be repaid in full on a change of control of the Company.

Interest on the Term Loan Facilities accrues at 10.50% per annum from the date of advance and is payable in cash on the first day of each month (an “Interest Payment Date”). Interest on the Convertible Facilities accrues at a rate of 10.95% per annum and is capitalised and added to the principal amount of the relevant tranche on each Interest Payment Date.

The Lender may convert all or part of the outstanding principal of the Convertible Facilities (including capitalised interest) into Ordinary Shares at a 30% premium to the equity fundraising price announced on 23 July 2026 (subject to adjustment for the Share Consolidation).

The Company may elect to prepay the Loan Facility in full, subject to payment of a prepayment fee.

The Loan Agreement contains customary representations, warranties, covenants and events of default for a facility of this type and size (including a requirement to hold certain minimum amounts of cash subject to security in favour of the Lender). The Company’s obligations are guaranteed by its wholly owned subsidiary, Scancell Limited, and secured over substantially all assets of the Company and Scancell Limited.

Warrants

In connection with the Loan Facility, the Company will grant warrants to subscribe for Ordinary Shares (“Warrants”) pro rata to drawdowns under the Loan Facility to Kreos Capital VIII Aggregator SCSp, an affiliate of the Lender (the “Warrantholder”).

The number of Ordinary Shares issued to the Warrantholder (“Warrant Shares”) will be determined at the point of exercise of the Warrants and will be equal to 4.5% of each drawdown amount divided by the Subscription Price.

The “Subscription Price” will be the lowest price paid per share in the Financing (subject to adjustment for the Share Consolidation), or if the Private Placement does not complete, [the lower of (a) the lowest price paid in any future equity financing round by the Company and (b)] the 30-day VWAP per Ordinary Share following an announcement that the Private Placement will not complete. The number of Warrant Shares and/or the Subscription Price are subject to customary adjustments. The Warrants are exercisable at any time up to the earlier of (i) 10 years from the date of the Loan Facility or (ii) a sale of the Company.

Shareholder Approval

Drawdowns under the Loan Facility and the issue of the Warrants are conditional upon shareholder approval at the EGM, [which the Company expects to hold in October 2026]. Further details of the Loan Facility and the EGM will be contained in the Circular and Notice of General Meeting, which will be announced and distributed to shareholders in due course.

Capitalised terms used but not otherwise defined in this announcement have the same meaning as defined in the Merger and Financing Announcement.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR) as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018.

The person responsible for arranging for the release of this announcement on behalf of Scancell is Phillip L’Huillier, Chief Executive Officer.

About iSCIB1+
iSCIB1+ is a DNA ImmunoBody^® in development for the treatment of melanoma. Administered by needle-free intramuscular injection, iSCIB1+ encodes an antibody targeting the melanoma-associated antigens gp100 and TRP-2, priming high-avidity T cells to generate a robust and durable anti-tumor response. In the Phase 2 SCOPE trial in first-line advanced melanoma, iSCIB1+ in combination with ipilimumab and nivolumab demonstrated a PFS of 77% at 22 months in the target HLA population, with no increase in checkpoint inhibitor-related toxicities. iSCIB1+ has demonstrated a favorable safety profile and clinically meaningful activity as a monotherapy in Phase 1 and in combination with checkpoint inhibitors in the Phase 2 SCOPE trial in advanced melanoma.

iSCIB1+ has been granted Fast Track Designation for the treatment of advanced melanoma from the FDA. The registrational Phase 3 trial of iSCIB1+ in patients with advanced melanoma has received an IND clearance from the FDA and CTA from the UK MHRA and is expected to begin in the second half of 2026. A Phase 2 trial of iSCIB1+ in patients with neo/adjuvant melanoma is planned for the first half of 2027.

iSCIB1+ is an investigational medicinal product. It has not been approved by the MHRA, the FDA or any other regulatory authority for the treatment of melanoma or any other indication, and its safety and efficacy have not been established.

Scancell (LSE:SCLP; www.scancell.co.uk) is a late-stage clinical biotechnology company developing targeted, off-the-shelf, active immunotherapies, generated by the ImmunoBody^® and Moditope^® platforms, designed to stimulate durable anti-tumor responses. The lead product, iSCIB1+, is a DNA ImmunoBody^® that has demonstrated a favorable safety profile and clinically meaningful activity both as a monotherapy, in a Phase 1 trial, and in combination with checkpoint therapies in a Phase 2 trial in patients with melanoma. Modi-1 is a Moditope peptide currently being evaluated in a Phase 2 study in head & neck and renal cancers. In addition, Scancell is advancing a pipeline of high affinity GlyMab^® antibodies targeting tumor specific glycans, two of which have been licensed for further development to Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.

Additional Information

In connection with the proposed business combination (Business Combination) between Neuphoria Therapeutics Inc. (Neuphoria) and Scancell, Scancell and Neuphoria intend to file with the U.S. Securities and Exchange Commission (SEC) a Registration Statement on Form F-4 (Registration Statement) containing a preliminary proxy statement of Neuphoria and a preliminary prospectus of Scancell, and after the Registration Statement is declared effective, Neuphoria will mail a definitive proxy statement/prospectus related to the proposed Business Combination to its stockholders. This communication does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the proposed Business Combination. Neuphoria’s stockholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed Business Combination, as these materials will contain important information about Scancell, Neuphoria and the proposed Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed Business Combination will be mailed to stockholders of Neuphoria as of a record date to be established for voting on the proposed Business Combination. Stockholders of Neuphoria will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a written request to: Neuphoria Therapeutics Inc, 100 Summit Dr, Burlington, Massachusetts 01803.

Participants in the Solicitation
Neuphoria and its directors and executive officers may be deemed participants in the solicitation of proxies from Neuphoria’s stockholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description of their interests in Neuphoria is contained in Neuphoria’s proxy statement on Schedule 14A for the 2025 Annual Meeting, which was filed with the SEC on November 24, 2025 and is available free of charge at the SEC’s web site at www.sec.gov, or by directing a written request to Neuphoria Therapeutics Inc, 100 Summit Dr, Burlington, Massachusetts 01803. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed Business Combination when available.

Scancell and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Neuphoria in connection with the proposed Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed Business Combination will be included in the proxy statement/prospectus for the proposed Business Combination when available.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate”, “aim”, “continue”, “target” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements.

These statements include, but are not limited to, statements regarding: expectations regarding clinical benefits and availability of Scancell’s product candidates, including iSCIB1+ in advanced melanoma; expectations regarding the design, progress, timing, enrolment, randomization, scope, expansion, and results of Scancell’s existing and planned clinical trials, including Scancell’s Phase 3 registrational trial of iSCIB1+ in advanced melanoma and Phase 2 monotherapy trial of iSCIB1+ in patients with neo/adjuvant melanoma; the expected submission of clinical trial applications or investigational new drug applications; the timing and sufficiency of clinical trial outcomes to support potential approval of any of Scancell’s product candidates; the potential regulatory approval; and the timing, ability to close and anticipated benefits of the proposed Business Combination. Any forward-looking statements are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond Scancell’s control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions, including as a result of health epidemics or pandemics, war in Ukraine, the conflict in the Middle East, or global geopolitical tension, on Scancell’s business, financial position, strategy and anticipated milestones, including Scancell’s ability to conduct ongoing and planned clinical trials; Scancell’s ability to obtain a clinical supply of current or future product candidates; Scancell’s ability to obtain regulatory approval of its product candidates; Scancell’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Scancell’s need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes in inflation and interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict in the Middle East, and global geopolitical tension; Scancell’s ability to obtain, maintain and enforce intellectual property protection for any of its product candidates it is developing; the success of Scancell’s current and future collaborations, partnerships or licensing arrangements; the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations or agreements with respect to the Business Combination; the outcome of any legal proceedings that may be instituted against Neuphoria, Scancell, the combined company or others following this announcement of the Business Combination and any definitive agreements with respect thereto; the inability to complete the Business Combination due to the failure to obtain approval of the stockholders of Neuphoria, to obtain financing to complete the Business Combination or to satisfy other conditions to closing; changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; the ability to meet stock exchange listing standards following the consummation of the Business Combination; the risk that the Business Combination disrupts current plans and operations of Scancell as a result of the announcement and consummation of the Business Combination; the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain key relationships and retain its management and key employees; costs related to the Business Combination; changes in applicable laws or regulations; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Neuphoria’s Annual Report on Form 10-K for the fiscal year ended June 30, 2026 or in other documents filed by Neuphoria with the SEC. There may be additional risks that neither Scancell nor Neuphoria presently know or that Scancell and Neuphoria currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither Scancell nor Neuphoria undertakes any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Scancell and Neuphoria disclaim any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Scancell, Neuphoria or any of their respective directors, officers, employees, affiliates, agents, advisors or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication.

No Offer
This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

For more information please contact:

Scancell Holdings plc	+44 (0) 20 3709 5700
Phil L’Huillier, CEO
Panmure Liberum (Nominated Adviser and Joint Broker)	+44 (0) 20 7886 2500
Emma Earl, Will Goode, Mark Rogers
WG Partners LLP (Joint Broker) Claes Spang	+44 (0) 20 3705 9330
Investor and media relations Mandeep Sehmi	+44 (0) 20 3709 5700 mandeepsehmi@scancell.co.uk